Severe hemophilia B
MONDO:0015715Severe hemophilia B is a form of hemophilia B characterized by a large deficiency of factor IX leading to frequent spontaneous hemorrhage and abnormal bleeding as a result of minor injuries, or following surgery or tooth extraction.
Also known as: severe factor IX deficiency, severe haemophilia type B, severe hemophilia type B
22 clinical trials for this condition and its sub-types, 9 tagged with Severe hemophilia B itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Monthly shot could free kids with hemophilia from frequent infusions
Disease control CompletedThis study tests fitusiran, a monthly injection, in boys aged 1 to under 12 with severe hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). The goal is to find the right dose to safely lower a protein called antithrombin, which helps preven…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Battlefield plasma goes civil: can a powder save trauma victims?
Disease control CompletedThis study tested a freeze-dried plasma product that can be mixed with water in 6 minutes, avoiding the long thaw time of standard plasma. It included 42 trauma patients with severe bleeding who needed blood transfusions. The goal was to see if faster plasma delivery could improv…
Phase 3 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hemophilia shot shows early promise in small safety trial
Disease control CompletedThis early-phase study tested a new drug called MG1113, given as a shot under the skin, in 15 adults with severe hemophilia A or B. The main goal was to check safety and how the drug moves through the body. Participants received multiple doses to see if the drug is well-tolerated…
Phase 1 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New blood product could cut transfusions in major surgeries
Disease control CompletedThis study tested a pathogen-reduced version of cryoprecipitate, a blood product that helps blood clot, in 208 patients undergoing liver transplant or heart surgery. The goal was to see if having this product readily available could stop bleeding early and reduce the need for oth…
Phase 4 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New monitoring methods tested for haemophilia b treatment
Knowledge-focused CompletedThis completed study involved 15 people with severe haemophilia B who were already taking eftrenonacog-alfa, a clotting factor medicine. Researchers compared different lab tests to see which ones best measure factor IX activity in real-life conditions. The goal was to improve mon…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC